143 related articles for article (PubMed ID: 36243303)
1. Evidence-based support for phenotypic drug discovery in acute myeloid leukemia.
Vandersluis S; Reid JC; Orlando L; Bhatia M
Drug Discov Today; 2022 Dec; 27(12):103407. PubMed ID: 36243303
[TBL] [Abstract][Full Text] [Related]
2. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Walter RB; Appelbaum FR; Tallman MS; Weiss NS; Larson RA; Estey EH
Blood; 2010 Oct; 116(14):2420-8. PubMed ID: 20538802
[TBL] [Abstract][Full Text] [Related]
3. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti C; Anelli L; Zagaria A; Specchia G; Albano F
Expert Rev Hematol; 2017 Oct; 10(10):853-862. PubMed ID: 28814164
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
6. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
[TBL] [Abstract][Full Text] [Related]
7. Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers.
Crawford R; Sully K; Conroy R; Johnson C; Doward L; Bell T; Welch V; Peloquin F; Gater A
Patient; 2020 Feb; 13(1):83-102. PubMed ID: 31456136
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome.
Cucchi DGJ; Groen RWJ; Janssen JJWM; Cloos J
Drug Resist Updat; 2020 Dec; 53():100730. PubMed ID: 33096284
[TBL] [Abstract][Full Text] [Related]
9. Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress.
Xiang W; Lam YH; Periyasamy G; Chuah C
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270002
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
11. New drugs in AML: uses and abuses.
Estey EH; Gale RP; Sekeres MA
Leukemia; 2018 Jul; 32(7):1479-1481. PubMed ID: 29875431
[No Abstract] [Full Text] [Related]
12. What are the most promising new agents in acute myeloid leukemia?
Sallman DA; Lancet JE
Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
15. Identification of mast cells as a candidate significant target of immunotherapy for acute myeloid leukemia.
Jia M; Zhang H; Wang L; Zhao L; Fan S; Xi Y
Hematology; 2021 Dec; 26(1):284-294. PubMed ID: 33648435
[TBL] [Abstract][Full Text] [Related]
16. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
Donker ML; Ossenkoppele GJ
Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.
Patel C; Stenke L; Varma S; Lindberg ML; Björkholm M; Sjöberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet JP
Cancer; 2013 Aug; 119(16):3076-83. PubMed ID: 23674237
[TBL] [Abstract][Full Text] [Related]
19. New approaches in acute myeloid leukemia.
Blum W; Marcucci G
Best Pract Res Clin Haematol; 2008 Mar; 21(1):29-41. PubMed ID: 18342810
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
